Compare Recursion Pharmaceuticals Inc (RXRX) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while iShares 1 3 Year Treasury Bond ETF trades at $81.22 (market cap $26.68B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 12.5× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| RXRX | SHY | |
|---|---|---|
Market Cap | $2.14B | $26.68B |
Volume | 30,789,535 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $6.79 | $83.18 |
52-Week Low | $2.84 | $81.05 |
Typical Hold Time | 22 Days | 63 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
SHY, a US stock, trades at $81.16, up 0.04% on the day. Technical indicators are bearish, with moving averages signaling sell pressure and oscillators neutral. The stock faces resistance and support near $81. Recent corporate actions include dividend payments, with the latest at $0.24 per share. Financial ratios are unavailable in the provided data, limiting fundamental analysis.
The outlook for SHY is cautious due to bearish technical signals and a lack of current fundamental data. Investment opportunities may arise from dividend income, but risks include market volatility and reliance on broader economic conditions. Investors should seek updated financials for a complete assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
